Pentostatin in hairy cell leukemia: Treatment by the special exception mechanism

Jean L. Grem, Susan A. King, Bruce D. Cheson, Brian Leyland-jones, Robert E. Wittes

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

An analysis of the clinical outcomes in 66 patients with hairy cell leukemia treated with pentostain under the Special Exception mechanism of the Division of Cancer Treatment, National Cancer Institute, between 1983 and 1987 has revealed a favorable balance of risk and benefit. Hematologic parameters and performance status were improved in most patients treated outside the clinical trials mechanism. The treating physicians considered 37 patients (56%) to be complete responders and 15 patients (23%) to be partial responders. Four patients (6%) died while receiving pentostatin. Life-threatening leukopenia (wbc count, <1,000/mm3) was reported in 24% of patients, and severe or life-threatening infection occurred in 11%. The experience gained with these patients supplements the information presently being collected from the controlled clinical trails and supports the development of a group C treatment protocol. [J Natl Cancer Inst 81:448-453, 1989]

Original languageEnglish (US)
Pages (from-to)448-453
Number of pages6
JournalJournal of the National Cancer Institute
Volume81
Issue number6
DOIs
StatePublished - Mar 15 1989

Fingerprint

Pentostatin
Hairy Cell Leukemia
Therapeutics
National Cancer Institute (U.S.)
Leukopenia
Clinical Protocols
Neoplasms
Clinical Trials
Physicians
Infection

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Pentostatin in hairy cell leukemia : Treatment by the special exception mechanism. / Grem, Jean L.; King, Susan A.; Cheson, Bruce D.; Leyland-jones, Brian; Wittes, Robert E.

In: Journal of the National Cancer Institute, Vol. 81, No. 6, 15.03.1989, p. 448-453.

Research output: Contribution to journalArticle

Grem, Jean L. ; King, Susan A. ; Cheson, Bruce D. ; Leyland-jones, Brian ; Wittes, Robert E. / Pentostatin in hairy cell leukemia : Treatment by the special exception mechanism. In: Journal of the National Cancer Institute. 1989 ; Vol. 81, No. 6. pp. 448-453.
@article{650d68319e1943889233cba5ef4f3b02,
title = "Pentostatin in hairy cell leukemia: Treatment by the special exception mechanism",
abstract = "An analysis of the clinical outcomes in 66 patients with hairy cell leukemia treated with pentostain under the Special Exception mechanism of the Division of Cancer Treatment, National Cancer Institute, between 1983 and 1987 has revealed a favorable balance of risk and benefit. Hematologic parameters and performance status were improved in most patients treated outside the clinical trials mechanism. The treating physicians considered 37 patients (56{\%}) to be complete responders and 15 patients (23{\%}) to be partial responders. Four patients (6{\%}) died while receiving pentostatin. Life-threatening leukopenia (wbc count, <1,000/mm3) was reported in 24{\%} of patients, and severe or life-threatening infection occurred in 11{\%}. The experience gained with these patients supplements the information presently being collected from the controlled clinical trails and supports the development of a group C treatment protocol. [J Natl Cancer Inst 81:448-453, 1989]",
author = "Grem, {Jean L.} and King, {Susan A.} and Cheson, {Bruce D.} and Brian Leyland-jones and Wittes, {Robert E.}",
year = "1989",
month = "3",
day = "15",
doi = "10.1093/jnci/81.6.448",
language = "English (US)",
volume = "81",
pages = "448--453",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Pentostatin in hairy cell leukemia

T2 - Treatment by the special exception mechanism

AU - Grem, Jean L.

AU - King, Susan A.

AU - Cheson, Bruce D.

AU - Leyland-jones, Brian

AU - Wittes, Robert E.

PY - 1989/3/15

Y1 - 1989/3/15

N2 - An analysis of the clinical outcomes in 66 patients with hairy cell leukemia treated with pentostain under the Special Exception mechanism of the Division of Cancer Treatment, National Cancer Institute, between 1983 and 1987 has revealed a favorable balance of risk and benefit. Hematologic parameters and performance status were improved in most patients treated outside the clinical trials mechanism. The treating physicians considered 37 patients (56%) to be complete responders and 15 patients (23%) to be partial responders. Four patients (6%) died while receiving pentostatin. Life-threatening leukopenia (wbc count, <1,000/mm3) was reported in 24% of patients, and severe or life-threatening infection occurred in 11%. The experience gained with these patients supplements the information presently being collected from the controlled clinical trails and supports the development of a group C treatment protocol. [J Natl Cancer Inst 81:448-453, 1989]

AB - An analysis of the clinical outcomes in 66 patients with hairy cell leukemia treated with pentostain under the Special Exception mechanism of the Division of Cancer Treatment, National Cancer Institute, between 1983 and 1987 has revealed a favorable balance of risk and benefit. Hematologic parameters and performance status were improved in most patients treated outside the clinical trials mechanism. The treating physicians considered 37 patients (56%) to be complete responders and 15 patients (23%) to be partial responders. Four patients (6%) died while receiving pentostatin. Life-threatening leukopenia (wbc count, <1,000/mm3) was reported in 24% of patients, and severe or life-threatening infection occurred in 11%. The experience gained with these patients supplements the information presently being collected from the controlled clinical trails and supports the development of a group C treatment protocol. [J Natl Cancer Inst 81:448-453, 1989]

UR - http://www.scopus.com/inward/record.url?scp=0024578592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024578592&partnerID=8YFLogxK

U2 - 10.1093/jnci/81.6.448

DO - 10.1093/jnci/81.6.448

M3 - Article

C2 - 2783980

AN - SCOPUS:0024578592

VL - 81

SP - 448

EP - 453

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 6

ER -